Translational and Clinical Research on Cancer: Glycomics Applications

癌症的转化和临床研究：糖组学应用

• 批准号: 7674436
• 负责人: J. Michael Pierce
• 金额: $ 3万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-20 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7674436
• 关键词: Antibodies; Area; Biological Markers; Blood Tests; Breast Carcinoma; Clinical; Clinical Research; Collaborations; Detection; Development; Diagnosis; Diagnostic; Disease; Disease Marker; Educational workshop; Fostering; Funding Agency; Glycopeptides; Glycoproteins; Hepatitis; Japan; Joints; Liquid substance; Malignant Neoplasms; Participant; Polysaccharides; Primary carcinoma of the liver cells; Printing; Research; Research Personnel; Sensitivity and Specificity; Serum; Specificity; Staging; Structure; Technology; United States; cancer diagnosis; clinical application; human tissue; innovation; meetings; new technology; novel; programs; public health relevance; symposium; technology/technique

DESCRIPTION (provided by applicant): The emerging field of Glycomics, the study of the structure and function of glycans, is poised to have a significant impact on the field of cancer biomarker discovery. Groups mainly concentrated in Japan and the United States have developed new technologies that allow a comprehensive analysis of glycans and glycopeptides from diseased human tissues and fluids as a means to identify potential cancer and other disease markers. Moreover, microarrays of printed glycans are available to identify auto-antibodies in serum that may serve as potential cancer biomarkers. Initial results from studies using these technologies are promising and suggest that Glycomics will yield novel biomarkers for specific cancers and provide increased specificity over those now available. Very recent results suggest detection of glycoforms of additional glycoproteins may provide diagnosis of progression of hepatitis to hepatocellular carcinoma with even higher specificity and sensitivity. Because of these and other results, governmental funding agencies in both Japan and the United States have begun programs to foster cancer glycomics biomarker research. The joint Japan-U.S. workshop, Glycomics applications for clinical cancer biomarker discovery, will bring together 40 world-class investigators who specialize in developing Glycomics technologies and applying them to the discovery of disease biomarkers. Glycomics research is just at the point where the presentation and discussion of recent advances applied to disease biomarkers are critical to the rapid development toward clinical and translational applications. No workshop or conference of this kind has yet been held. The opportunity to have an innovative workshop such as this will greatly accelerate the development of cancer biomarkers by providing a means to share newly developed techniques and technologies and allowing participants to develop specific collaborations. Public Health Relevance: This meeting will bring together researchers from around the world who apply findings in an area of research known as Glycomics to the development of cancer markers, particularly diagnostics. The meeting is expected to accelerate the development and testing of blood markers for several cancers. Having access to these types of diagnostic markers would facilitate an early, non- invasive diagnosis of cancers such as hepatocellular carcinoma and breast carcinoma, thereby allowing them to be treated at a early stage.

描述(由申请人提供)：糖链学这一新兴领域，即研究多糖的结构和功能，将对癌症生物标记物的发现领域产生重大影响。主要集中在日本和美国的组织开发了新技术，可以对患病人体组织和体液中的多糖和糖肽进行全面分析，以此作为识别潜在癌症和其他疾病标志物的手段。此外，印制的葡聚糖微阵列可用于识别血清中可能作为潜在癌症生物标志物的自身抗体。使用这些技术的研究的初步结果是有希望的，并表明Glycomics将为特定的癌症产生新的生物标记物，并提供比现有的更高的特异性。最新的结果表明，检测额外糖蛋白的糖形式可以提供更高的特异性和敏感度来诊断肝炎进展为肝细胞癌。由于这些和其他结果，日本和美国的政府资助机构都开始了促进癌症糖组分生物标记物研究的计划。这个名为Glycomics Applications for临床癌症生物标记物发现的日美联合研讨会将汇集40名世界级的研究人员，他们专门开发Glycomics技术并将其应用于疾病生物标记物的发现。Glycomics的研究正处于展示和讨论应用于疾病生物标记物的最新进展对于快速发展临床和翻译应用的关键时刻。目前还没有举办过这样的研讨会或会议。有机会举办这样一次创新的研讨会，将提供一种分享新开发的技术和技术的手段，并使与会者能够开展具体的合作，从而大大加快癌症生物标记物的开发。 公共卫生相关性：这次会议将汇聚来自世界各地的研究人员，他们将把血糖学研究领域的研究成果应用于癌症标记物的开发，特别是诊断学。预计这次会议将加快几种癌症血液标记物的开发和测试。获得这些类型的诊断标记物将有助于对肝细胞癌和乳腺癌等癌症进行早期、非侵入性诊断，从而使它们能够在早期阶段得到治疗。